These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7213793)

  • 21. Stimulating effects of angiotensin I, angiotensin II and des-Asp1-angiotensin II on steroid production in vitro and its inhibition by Sar1-Ala8-angiotensin II.
    Hepp R; Grillet C; Peytremann A; Vallotton MB
    Prog Biochem Pharmacol; 1976; 12():41-8. PubMed ID: 1019169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational analysis of the type II and type III collagen alpha-1 chain C-telopeptides by 1H NMR and circular dichroism spectroscopy.
    Liu X; Otter A; Scott PG; Cann JR; Kotovych G
    J Biomol Struct Dyn; 1993 Dec; 11(3):541-55. PubMed ID: 8129872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and dynamics of the neutrophil defensins NP-2, NP-5, and HNP-1: NMR studies of amide hydrogen exchange kinetics.
    Skalicky JJ; Selsted ME; Pardi A
    Proteins; 1994 Sep; 20(1):52-67. PubMed ID: 7824523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solution conformation of thymopoietin32-36: a proton nuclear magnetic resonance study.
    Krishna NR; Huang DH; Chen DM; Goldstein G
    Biochemistry; 1980 Nov; 19(24):5557-63. PubMed ID: 7459332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
    Zawada ET; Stinson J; Ramirez G
    Postgrad Med; 1980 Oct; 68(4):89-92, 94-5, 98. PubMed ID: 6999479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of adrenal arterial infusion of saralasin (P113) on aldosterone secretion.
    Blair-West JR; Coghlan JP; Denton DA; Niall HD; Scoggins BA; Tregear GW
    Prog Biochem Pharmacol; 1976; 12():53-62. PubMed ID: 1019170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Historical development of saralasin.
    Pals DT; Denning GS; Keenan RE
    Kidney Int Suppl; 1979 Mar; (9):S7-10. PubMed ID: 384071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma vasopressin in conscious goats after cerebroventricular infusions of angiotensins, sodium chloride, and fructose.
    Fyhrquist F; Eriksson L; Wallenius M
    Endocrinology; 1979 Apr; 104(4):1091-5. PubMed ID: 436751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologic studies with saralasin in animals.
    Gavras H; Gavras I; Brunner HR; Liang CS
    Kidney Int Suppl; 1979 Mar; (9):S20-8. PubMed ID: 384069
    [No Abstract]   [Full Text] [Related]  

  • 30. Lack of specific inhibition of angiotensin II in eels by angiotensin antagonists.
    Nishimura H; Norton VM; Bumpus FM
    Am J Physiol; 1978 Jul; 235(1):H95-103. PubMed ID: 677333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor.
    Morton JJ; Casals-Stenzel J; Lever AF; Millar JA; Riegger AJ; Tree M
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):233S-241S. PubMed ID: 223615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of the biological activity and solution conformation of [Asp1,Ile5]- and [Phe4,Tyr8]angiotensin II.
    Bleich HE; Freer RJ; Stafford SS; Galardy RE
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3630-4. PubMed ID: 29291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amide proton exchange rates of a bound pepsin inhibitor determined by isotope-edited proton NMR experiments.
    Fesik SW; Luly JR; Stein HH; BaMaung N
    Biochem Biophys Res Commun; 1987 Sep; 147(3):892-8. PubMed ID: 2822045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton nuclear magnetic resonance study of an active pentapeptide fragment of ubiquitin.
    Krishna NR; Huang DH; Vaughn JB; Heavner GA; Goldstein G
    Biochemistry; 1981 Jun; 20(13):3933-40. PubMed ID: 6268154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of angiotensin III by angiotensin-converting enzyme.
    Chiu AT; Ryan JW; Stewart JM; Dorer FE
    Biochem J; 1976 Apr; 155(1):189-92. PubMed ID: 180981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of angiotensin II receptor blockade by [Sar1-Ala8]angiotensin II in hemorrhagic shock.
    Trachte GJ; Lefer AM
    Am J Physiol; 1979 Feb; 236(2):H280-5. PubMed ID: 311160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of Peptide Polymer Interactions in Poly(alkylcyanoacrylate) Nanoparticles: A Mass Spectrometric Approach.
    Kafka AP; Kleffmann T; Rades T; McDowell A
    Curr Drug Deliv; 2010 Jul; 7(3):208-15. PubMed ID: 20497104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational analysis of the type II and type III collagen alpha-1 chain N-telopeptides by 1H-NMR spectroscopy and restrained molecular mechanics calculations.
    Otter A; Scott PG; Kotovych G
    Biopolymers; 1993 Sep; 33(9):1443-59. PubMed ID: 8400034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients.
    Pettinger WA; Keeton K; Tanaka K
    Clin Pharmacol Ther; 1975 Feb; 17(2):146-58. PubMed ID: 1168111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide-binding macromolecules in the blood of seriously ill or mentally retarded patients.
    Goodfriend TL; Sindel M; Fyhrquist F; Hong R; Azen E; Stewart JM
    J Lab Clin Med; 1976 Feb; 87(2):299-319. PubMed ID: 1455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.